Paul J Kostenuik

US Patent:

20030039654, Feb 27, 2003

Filed:

Apr 26, 2001

Appl. No.:

09/843221

Inventors:

Paul Kostenuik - Newbury Park CA, US
David Lacey - Newbury Park CA, US

Assignee:

Amgen Inc.

International Classification:

A61K039/395
A61K031/66
A61K038/17

US Classification:

424/178100, 514/012000, 514/102000

Abstract:

The present invention concerns therapeutic agents that modulate the activity of PTH and PTHrP. In accordance with the present invention, modulators of PTH and PTHrP comprise: (a) a PTH/PTHrP modulating domain; and (b) a vehicle, such as a polymer (e.g., PEG or dextran) or an Fc domain, which is preferred; wherein the vehicle is covalently attached to the C-terminus of the PTH/PTHrP modulating domain. The vehicle and the PTH/PTHrP modulating domain may be linked through the N- or C-terminus of the PTH/PTHrP modulating domain, as described further below. The preferred vehicle is an Fc domain, and the preferred Fc domain is an IgG Fc domain. Preferred PTH/PTHrP modulating domains comprise the PTH and PTHrP-derived amino acid sequences described hereinafter. Other PTH/PTHrP modulating domains can be generated by phage display, RNA-peptide screening and the other techniques mentioned herein. Such peptides typically will be modulators of both PTH activity and PTHrP activity, although such techniques can be used to generate peptide sequences that serve as selective modulators (e.g., agonists of PTH activity but not PTHrP activity).

US Patent:

20040214996, Oct 28, 2004

Filed:

May 4, 2004

Appl. No.:

10/839037

Inventors:

Paul Kostenuik - Newbury Park CA, US
David Lacey - Newbury Park CA, US

Assignee:

Amgen Inc.

International Classification:

C07K016/46

US Classification:

530/391100

Abstract:

The present invention concerns therapeutic agents that modulate the activity of PTH and PTHrP. In accordance with the present invention, modulators of PTH and PTHrP comprise: (a) a PTH/PTHrP modulating domain; and (b) a vehicle, such as a polymer (e.g., PEG or dextran) or an Fc domain, which is preferred; wherein the vehicle is covalently attached to the C-terminus of the PTH/PTHrP modulating domain. The vehicle and the PTH/PTHrP modulating domain may be linked through the N— or C-terminus of the PTH/PTHrP modulating domain, as described further below. The preferred vehicle is an Fc domain, and the preferred Fc domain is an IgG Fc domain. Preferred PTH/PTHrP modulating domains comprise the PTH and PTHrP-derived amino acid sequences described hereinafter. Other PTH/PTHrP modulating domains can be generated by phage display, RNA-peptide screening and the other techniques mentioned herein. Such peptides typically will be modulators of both PTH activity and PTHrP activity, although such techniques can be used to generate peptide sequences that serve as selective modulators (e.g., agonists of PTH activity but not PTHrP activity).

US Patent:

20050124537, Jun 9, 2005

Filed:

Oct 31, 2001

Appl. No.:

09/999608

Inventors:

Paul Kostenuik - Newbury Park CA, US
Colin Gegg - Newbury Park CA, US
Mark Jarosinski - Boulder CO, US
Olaf Kinstler - Newbury Park CA, US

International Classification:

C07K014/635
A61K038/29

US Classification:

514012000, 530399000

Abstract:

The present invention concerns therapeutic agents that modulate the activity of PTH and PTHrP. In accordance with the present invention, modulators of PTH and PTHrP comprise: (a) a PTH/PTHrP modulating domain; and (b) a vehicle, such as a polymer (e.g., PEG or dextran) or an Fc domain, which is preferred; wherein the vehicle is covalently attached to the C-terminus of the PTH/PTHrP modulating domain or through a sidechain at any residue from residue 14 through the C-terminal residue. The vehicle and the PTH/PTHrP modulating domain may be linked through the N- or C-terminus of the PTH/PTHrP modulating domain, as described further below. The preferred vehicle is PEG. Preferred PTH/PTHrP modulating domains comprise the PTH and PTHrP-derived amino acid sequences described hereinafter. Other PTH/PTHrP modulating domains can be generated by phage display, RNA-peptide screening and the other techniques mentioned herein. Such peptides typically will be modulators of both PTH activity and PTHrP activity, although such techniques can be used to generate peptide sequences that serve as selective modulators (e.g., agonists of PTH activity but not PTHrP activity).

US Patent:

20070134245, Jun 14, 2007

Filed:

Nov 13, 2006

Appl. No.:

11/599629

Inventors:

Paul Kostenuik - Newbury Park CA, US
Wenyan Shen - Palo Alto CA, US
Thomas Boone - Newbury Park CA, US

International Classification:

A61K 39/395
C07K 16/46
C07K 16/28

US Classification:

424145100, 424178100, 530388240, 530391100

Abstract:

Chimeric molecules comprising receptor activator of NF-κB ligand (RANKL) antibodies and parathyroid hormone/parathyroid hormone-related protein (PTH/PTHrP) peptides are described. Compositions and methods for the treatment of bone diseases are also described.